References

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials

10.1016/s0140-6736(14)60488-8 · 2014 · External reference

Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis

10.1136/bmj-2023-079089 · 2024 · External reference

Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial

10.1016/s1470-2045(18)30813-1 · 2019 · External reference

Postmastectomy radiation therapy: an ASTRO-ASCO-SSO clinical practice guideline

10.1200/jco-25-01747 · 2025 · External reference

European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer

10.1016/s1470-2045(21)00539-8 · 2022 · External reference

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials

10.1016/s1470-2045(13)70386-3 · 2013 · External reference

Long-term results of hypofractionated radiation therapy for breast cancer

10.1056/nejmoa0906260 · 2010 · External reference

Late normal tissue effects in the arm and shoulder following lymphatic radiotherapy: Results from the UK START (Standardisation of Breast Radiotherapy) trials

10.1016/j.radonc.2017.10.033 · 2018 · External reference

Late-term effects of hypofractionated chest wall and regional nodal radiotherapy with two-dimensional technique in patients with breast cancer

10.3857/roj.2020.00129 · 2020 · External reference

Effect of elective internal mammary node irradiation on disease-free survival in women with node-positive breast cancer: a randomized phase 3 clinical trial

10.1001/jamaoncol.2021.6036 · 2022 · External reference

Regional nodal irradiation in early-stage breast cancer

10.1056/nejmoa1415340 · 2015 · External reference

Side effects 15 years after lymph node irradiation in breast cancer: randomized EORTC trial 22922/10925

10.1093/jnci/djab113 · 2021 · External reference

Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG 82bc trial

10.1016/j.radonc.2022.03.008 · 2022 · External reference

Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy

10.1016/j.ijrobp.2023.10.026 · 2024 · External reference

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

10.1016/s0140-6736(23)00619-0 · 2023 · External reference

Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial

10.1016/s0140-6736(20)30932-6 · 2020 · External reference

Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer

10.1093/jnci/94.15.1143 · 2002 · External reference

Spontaneous rib fractures after breast cancer treatment based on bone scans: comparison of conventional versus hypofractionated radiotherapy

10.1016/j.clbc.2020.07.009 · 2021 · External reference

Effects of tumor–rib distance and dose-dependent rib volume on radiation-induced rib fractures in patients with breast cancer

10.3390/jpm12020240 · 2022 · External reference

Toxicity evaluation of dose-escalation in hypofractionated regional nodal irradiation for breast cancer: a retrospective study

10.1016/j.ijrobp.2024.04.014 · 2024 · External reference

5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial

10.1016/s0140-6736(25)02597-8 · 2026 · External reference

5027 DBCG Skagen trial 1: phase III randomised trial of hypo- vs standard fractionated loco-regional radiotherapy in node-positive breast cancer patients

10.1016/s0167-8140(25)04203-3 · 2025 · External reference

Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-study

10.1016/j.radonc.2025.110915 · 2025 · External reference

Intensity-modulated radiation therapy for early-stage breast cancer: a systematic review and meta-analysis

2024 · External reference

A randomized trial of hypofractionated post-mastectomy radiation therapy (PMRT) in women with breast reconstruction (RT CHARM, Alliance A221505)

10.1016/j.ijrobp.2024.07.002 · 2024 · External reference

Hypofractionated vs conventionally fractionated postmastectomy radiation after implant-based reconstruction: a randomized clinical trial

10.1001/jamaoncol.2024.2652 · 2024 · External reference

Comparison of hypofractionation and conventional fractionation in postmastectomy radiotherapy after immediate breast reconstruction: a systematic review and meta-analysis of complications

10.1016/j.ejca.2025.115669 · 2025 · External reference

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial

10.1200/jco.22.01565 · 2023 · External reference